ABL Bio signed a license and research agreement with Eli Lilly worth up to $2.6 billion to deploy its Grabody-B blood–brain-barrier shuttle across multiple CNS programs. The deal includes a $40 million up-front payment and potential development, regulatory and commercial milestones, plus tiered royalties. ABL’s Grabody-B platform, designed to ferry biologics across the BBB, gives Lilly options to expand its CNS pipeline and accelerate delivery modalities. Company releases noted undisclosed program counts and highlighted the strategic push by large pharma into brain-shuttle technologies.